0001209191-21-028813.txt : 20210428 0001209191-21-028813.hdr.sgml : 20210428 20210428164526 ACCESSION NUMBER: 0001209191-21-028813 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210426 FILED AS OF DATE: 20210428 DATE AS OF CHANGE: 20210428 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Kevin CENTRAL INDEX KEY: 0001776938 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 21864995 MAIL ADDRESS: STREET 1: C/O BICYCLE THERAPEUTICS LIMITED STREET 2: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB223AT ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-26 0 0001761612 BICYCLE THERAPEUTICS plc BCYC 0001776938 Lee Kevin C/O BICYCLE THERAPEUTICS PLC B900, BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT UNITED KINGDOM 1 1 0 0 Chief Executive Officer Ordinary Shares 2021-04-26 4 M 0 14545 14.00 A 273345 D Ordinary Shares 2021-04-26 4 S 0 4715 30.63 D 268630 D Ordinary Shares 2021-04-26 4 S 0 13896 31.50 D 254734 D Ordinary Shares 2021-04-27 4 M 0 6636 14.00 A 261370 D Ordinary Shares 2021-04-27 4 S 0 6278 30.66 D 255092 D Ordinary Shares 2021-04-27 4 S 0 358 31.41 D 254734 D Stock Option (Right to Buy) 14.00 2021-04-26 4 M 0 14545 0.00 D 2029-06-28 Ordinary Shares 14545 491707 D Stock Option (Right to Buy) 14.00 2021-04-26 4 M 0 6636 0.00 D 2029-06-28 Ordinary Shares 6636 485071 D Shares sold pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.07 to $31.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.73 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.31 to $31.27 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.39 to $31.46 inclusive. This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. /s/ Lee Kalowski, Attorney-in-Fact 2021-04-28